Neoadjuvant chemotherapy (NAC) is considered standard of care for locally advanced breast cancer. Pre- and post-NAC MRI is routinely used to assess response. This study aims to investigate pre- and post-NAC quantitative DCE-MRI parameters, alone and in combination with clinico-pathologic variables, for prediction of breast cancer recurrence following NAC. 47 patients underwent DCE-MRI studies pre- and post-NAC. The results show that quantitative pharmacokinetic DCE-MRI parameters, whether alone or in combination with clinico-pathologic variables, outperformed tumor size measurement by conventional imaging in prediction of recurrence. Furthermore, DCE-MRI parameters provided added value in predictive performance when combined with clinico-pathologic variables.
This abstract and the presentation materials are available to members only; a login is required.